Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs by Gelardi, T et al.










1 and G Tortora*,1
1Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita ` di Napoli Federico II, Napoli, Italy;
2Dipartimento Medico-Chirurgico
di Internistica Clinica e Sperimentale, Seconda Universita ` di Napoli, Napoli, Italy;
3Eli-Lilly and Company, Indianapolis, IN, USA
We investigated the antitumour effect and ability to overcome the resistance to anti-EGFR drugs of enzastaurin, an inhibitor of
VEGFR-dependent PKCb signalling. Enzastaurin was evaluated alone and in combination with the EGFR inhibitor gefitinib, on growth
and signalling protein expression in human cancer cells sensitive and resistant to anti-EGFR drugs, both in vitro and in nude mice. We
demonstrated the marked inhibitory activity of enzastaurin against GEO colon and PC3 prostate cancer cells and their gefitinib-
resistant counterparts GEO-GR and PC3-GR, accompanied by inhibition of pAkt and its effector pp70S6K, pGSK3b and VEGF
expression and secretion. Moreover, enzastaurin showed a cooperative effect with gefitinib in parental and in gefitinib-resistant cells.
Remarkably, these results were confirmed in vivo, where enzastaurin showed antitumour activity and cooperativity with gefitinib in
mice grafted with GEO and GEO-GR tumours, incrementing their median survival and inhibiting the aforesaid protein expression and
secretion in tumour specimens. In conclusion, enzastaurin by interfering with signalling proteins implicated in EGFR drug resistance
markedly cooperates with gefitinib in sensitive and gefitinib-resistant tumours, thus overcoming and reverting such resistance and
providing a rational basis for its development in patients resistant to anti-EGFR drugs.
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The epidermal growth factor receptor (EGFR) is a member of the
ErbB/HER family of receptor tyrosine kinases (TK), frequently
overexpressed in human tumours and directly implicated in the
control of cell growth, apoptosis and angiogenesis (Hynes and
Lane, 2005). Epidermal growth factor receptor blockade by
monoclonal antibodies or small molecule TK inhibitors (TKIs),
such as gefitinib or erlotinib, has now entered clinical practice in
patients affected by different types of cancer (Mendelsohn and
Baselga, 2006; Ciardiello and Tortora, 2008). However, this
therapeutic approach has limitations due to the constitutive and/
or acquired resistance to EGFR inhibitors, which represents an
important emerging problem in cancer treatment. Several groups,
including ours, have previously shown that colon tumours that
acquire resistance to the anti-EGFR drugs cetuximab or gefitinib
exhibit an activation of alternative downstream signal transduction
pathways, including increased activity and/or overexpression of
pMAPK and VEGF (Viloria-Petit et al, 2001; Ciardiello et al, 2004;
Morgillo and Lee, 2005). Therefore, novel agents that are able to
block the above signalling proteins are needed and may be
effective also in preventing and/or overcoming the resistance to
EGFR inhibitors. A number of inhibitors of VEGF or VEGF
receptors (VEGFRs) have already entered clinical practice (Shojaei
and Ferrara, 2007), whereas agents targeting signal transducers
of the VEGFR pathway are much fewer and are still under
evaluation.
The protein kinase C (PKC), particularly the PKCb isoform, is
involved in VEGFR signal transduction (Xia et al, 1996) and can
lead to the overproduction of VEGF, as well as to the inhibition of
apoptotic cell death (Yoshiji et al, 1999; Tsai et al, 2003). For all
these reasons, PKCb is recognised as a significant target for cancer
chemotherapy (Hofmann, 2004; Yan Liu et al, 2004). The acyclic
bisindolylmaleimide LY317615 (enzastaurin HCl) is a potent and
selective serine/threonine kinase inhibitor, initially developed as
an antiangiogenic adenosine triphosphatase-competitive selective
inhibitor of PKCb (Faul et al, 2003). Enzastaurin dramatically
suppressed the growth of new vasculature towards a VEGF-
impregnated disc implanted in the rat corneal micropocket
(Teicher et al, 2002) and decreased microvessel density and
plasma VEGF levels in human tumour xenografts (Keyes et al,
2004; Graff et al, 2005). Enzastaurin has also been tested in
combination with radiotherapy in glioma cells (Tabatabai et al,
2007). In animal models, enzastaurin showed antitumour and
antiangiogenic activity in a wide array of human tumours,
including non-small cell lung (NSCL), colon, renal cell and
hepatocellular carcinomas (Keyes et al, 2002; Liu et al, 2004).
Enzastaurin has entered clinical evaluation showing good tolera-
bility, manageable side effects and significant activity in patients
with lymphomas (Carducci et al, 2006) and pretreated high-grade
glioblastomas (Fine et al, 2005). Enzastaurin has also been
tested in combination with gemcitabine and cisplatin and with Revised 30 May 2008; accepted 12 June 2008
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scapecitabine in patients with advanced cancer (Beerepoot et al,
2007; Leong et al, 2008).
Preclinical and clinical studies suggest that enzastaurin may
have an activity broader than PKCb inhibition. Moreover, we have
hypothesised that its antiangiogenic effects may be exploited to
antagonise the resistance to anti-EGFR drugs. Therefore, in the
present study, we have evaluated whether enzastaurin is able to
inhibit the growth in vitro and in nude mice of a variety of human
tumours with different degree of expression of EGFR and PKCb,
including those with acquired or spontaneous resistance to the
EGFR inhibitor gefitinib, correlating the effect with the expression
of proteins involved in the acquisition of resistance to anti-EGFR
drugs. Finally, we have investigated whether enzastaurin is able to
revert the resistance to gefitinib.
MATERIALS AND METHODS
Drugs
Gefitinib was kindly provided by AstraZeneca Pharmaceuticals
(Macclesfield, UK). Enzastaurin was kindly provided by Ely Lilly
(Indianapolis, IN, USA).
Cell cultures
Human GEO colon, PC3 hormone-refractory prostate, MDA-MB-
468 breast, SKLU-1 and GLC-82 non-small lung, and PACA44,
PANC1 and HPAF pancreatic cancer cells were obtained from the
American Type Culture Collection (Manassas, VA, USA). GEO-GR
(gefitinib-resistant), GEO-CR (cetuximab-resistant) and PC3-GR
(gefitinib-resistant) cells were established as previously described
(Ciardiello et al, 2004). The resulting cell lines that were stably
resistant to EGFR inhibitors retained a resistant phenotype even
after several passages in the absence of EGFR antagonists. All
cell lines were cultured as previously described (Ciardiello et al,
2004).
Growth in soft agar and analysis of combination index
On day 0, cells were suspended in 0.3% Difco Noble agar (Difco,
Detroit, MI, USA) supplemented with complete culture medium,
layered over 0.5ml of 0.8% agar medium base and treated with
different concentrations of enzastaurin and gefitinib alone or in
combination. After 10–14 days, cells were stained with nitro blue
tetrazolium (Sigma Chemical Co., Milan, Italy), and colonies
40.05mm were counted (Ciardiello et al, 2001). Assessment of
synergy was performed following the method described by Chou
and Talalay (1984) and using the Calcusyn software program
(Biosoft, Cambridge, UK). According to this method, combination
index (CI) values of o1, 1 and 41 indicate synergy, additivity and
antagonism, respectively.
Cell survival assay
Cells were grown in 24-well plates in the presence of enzastaurin
(0.5–2.5mM). After removing supernatant, 1mgml
 1 of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-
Aldrich, Milan, Italy) solution in medium was added to each well.
After adding isopropanol, absorbance was measured at 570nm.
Western blot analysis
Total cell lysates were obtained from cells cultured in vitro or
from homogenised tumour. The protein extracts were resolved
by 4–15% SDS–PAGE and probed with anti-human, polyclonal
Akt, monoclonal pAkt, (Cell Signaling Technologies, Beverly, MA,
USA), monoclonal actin (Sigma-Aldrich, Milan, Italy), polyclonal
p70S6K and polyclonal pp70S6K (Santa Cruz Biotechnology, CA,
USA), monoclonal VEGF, polyclonal pGSK3b and polyclonal
GSK3b (Cell Signaling Technologies). Immunoreactive proteins
were visualised by enhanced chemiluminescence (Pierce,
Rockford, IL, USA), as described previously (Ciardiello et al, 2001).
Apoptosis detection in cultured cells
The induction of apoptosis was measured using the Cell Death
Detection ELISA Plus Kit (Roche Molecular Biochemicals,
Mannheim, Germany) (Ciardiello et al, 2004). Briefly, cells
(5 10
4 cells per well) were seeded into six-multiwell cluster
dishes and treated on days 1–2 with enzastaurin (1 and 2.5mM).
Each treatment was performed in quadruplicate. Absorbance
readings at 405nm were normalised for cell number, and the ratio
of absorbance of treated cells/untreated cells was defined as the
apoptotic index (AI).
Cell cycle distribution
Cell cycles were measured using YO-PRO-1/propidium iodide
(Molecular Probes, Eugene, OR, USA). Cells stained with YO-
PRO-1 and propidium iodide were analysed by flow cytometry.
After overnight incubation, the cells were exposed to the
following treatments at days 1 and 2: enzastaurin 1 and 2.5mM.
After each treatment, cells and medium were collected, washed
once in PBS and aliquoted. For cell cycle analysis, cells were
resuspended in Krishan’s stain and allowed to incubate at 41C for
a minimum of 6h before analysis. Cell cycle data analysis
was performed using the CELL-FIT software (Becton Dickinson,
San Jose, CA, USA).
ELISA assay
The concentrations of hVEGF and murine serum VEGF (mVEGF)
in protein extracts or conditioned media from tumour cell lines
treated with enzastaurin 1mM for 48h were determined by ELISA,
as previously described (Errico et al, 2004). The absorbance was
measured at 490nm on a microplate reader (Bio-Rad, Hercules,
CA, USA). VEGF concentrations were determined by interpolation
of the standard curve using linear regression analysis.
Xenografts in nude mice
Five-week-old Balb/cAnNCrlBR athymic (nuþ/nuþ) mice
(Charles River Laboratories, Milan, Italy) were maintained in
accordance with institutional guidelines of the University of Naples
Animal Care Committee and in accordance with the Declaration of
Helsinki. GEO and GEO-GR human colon cancer cells (10
7 cells per
mice) were resuspended in 200ml of Matrigel (Collaborative
Biomedical Products, Bedford, MA, USA) and injected subcuta-
neously into mice. After 7 days, when the tumours reached a group
mean of 100mm
3, tumours were detected and groups of 10 mice
were randomised to receive the following treatments: intra-
peritoneal gefitinib at 150mgkg
 1 thrice weekly, enzastaurin by
gavage twice daily at 75mgkg
 1 based on weekly body measure-
ments for each treated group. Tumour volume was measured
using the formula p/6 larger diameter (smaller diameter)
2 as
previously reported (Ciardiello et al, 1996). Two mice were killed
on day 25 to perform biochemical analysis. All mice were killed
when tumour volume reached 2cm
3.
Statistical analysis
The Student’s t-test was used to evaluate the statistical significance
of the results. All reported P-values were two-sided. All analyses
were performed with the BMDP New System statistical package
Enzastaurin activity in anti-EGFR drug-resistant tumours
T Gelardi et al
474

























sversion 1.0 for Microsoft Windows (BMDP Statistical Software, Los
Angeles, CA, USA).
RESULTS
Effect of enzastaurin on the growth of human cancer cell
lines with a different degree of sensitivity or resistance to
EGFR inhibitors
To test the antiproliferative effect of enzastaurin on cancer cell
growth, we treated with different doses of enzastaurin several
human cancer cell lines growing in soft agar with established
differential sensitivity to EGFR inhibitors, including colon GEO,
prostate PC3 and breast MDA-468 cells. GEO cells express low
levels of EGFR and are sensitive to both cetuximab and gefitinib,
whereas GEO-CR and GEO-GR are highly resistant to both drugs.
PC3 possesses similar levels of EGFR and similar sensitivity
to gefitinib compared to GEO, opposite to PC3-GR, which
are gefitinib-resistant. MDA-MB-468 express high levels of EGFR,
yet they are relatively resistant to gefitinib (Bianco et al, 2003) and
cetuximab (up to 20mgml
 1). GEO cells and derivatives express
the wild-type functional form of PTEN, whereas it is deleted and
mutated in PC3 and MDA-468 cells, respectively.
Enzastaurin caused a dose-dependent inhibition of colony
formation with an IC50 of approximately 1mM for all cancer cell
lines tested (Figure 1). In MTT cell survival assay, enzastaurin
caused a similar effect to that obtained in the soft agar assay, with
an IC50 of 1mM for all cancer cell lines tested. We also tested the
effect of enzastaurin treatment on tumour growth in other EGFR-
expressing cancer cell lines, including SKLU-1 and GLC-82 (NSCL
cancer) and PACA44, PANC1 and HPAF (pancreatic cancer cells).
Enzastaurin caused a dose-dependent inhibition of colony
formation with an IC50 of 1mM for PACA44, PANC1 and GLC82,
and 0.5–1mM for HPAF and SKLU-1.
We evaluated if the enzastaurin-induced antiproliferative effect
was accompanied by induction of programmed cell death. We
observed a dose-dependent increase in apoptosis in all human
cancer cell lines treated with enzastaurin, as the treatment caused
an increase in the AI of 1.5- to 2.5-fold compared with untreated
cells. We performed a cell cycle distribution analysis after
enzastaurin treatment in all cancer cells, and we observed no
perturbations (data not shown).
Enzastaurin inhibits the PI3K-dependent pathway and
reduces the VEGF levels in cell lysate and conditioned
medium
We evaluated by western blot analysis the effect of treatment on
the expression of proteins involved in the PI3K pathway. We
observed that enzastaurin had no effect on total Akt, p70S6K and
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Figure 1 GEO, GEO-CR, GEO-GR, PC3, PC3-GR and MDA-468 cells were treated with enzastaurin at doses of drug ranged from 0.1 to 5mM. Data are
expressed as the number of colony formation. Data represent the average of triplicate determinations of at least two experiments.
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sGSK3b levels, whereas it markedly inhibited the activated pAkt, its
effector pp70S6K and pGSK3b levels (Figure 2A).
To investigate the effects of enzastaurin treatment on the
production of the main angiogenic growth factor VEGF, the cell
lysate and the conditioned medium obtained from the various cell
lines treated with enzastaurin were collected and analysed for the
presence of VEGF by ELISA assay. As shown in Figure 2B and C,
an inhibition of the expression and secretion of VEGF was
observed in all cancer cell lines tested, particularly in the EGFR
inhibitor-resistant cells.
Combination treatment of enzastaurin and gefitinib shows
a synergism of action in cancer cell lines
We evaluated whether enzastaurin and gefitinib in combination
were able to cooperate in inhibiting human cancer cell growth of
GEO, GEO-GR, PC3 and PC3-GR. We selected different doses of
enzastaurin (0.05–1mM) and gefitinib (0.05–1mM) and used them
alone and in combination. We used different schedules of
administration (enzastaurin followed by gefitinib vs gefitinib
followed by enzastaurin vs simultaneous enzastaurin and gefitinib)
and found that the simultaneous administration was the most
efficient to inhibit the tumour growth. The effects of drugs, alone
and in combination at fixed molar ratios, according to the method
of Chou and Talalay (1984), are summarised in the dose–response
fit curves generated (Figure 3A and B). To better evaluate the
interaction and the possible cooperation between enzastaurin and
gefitinib, we performed a combination analysis at their equipotent
ratio and generated CI and isobologram curves, according to Chou
and Talalay (1984), using an automated calculation software.
Values of CIo1 indicate synergism. The combination caused a
synergism of action on the soft agar growth in all tested cell lines.
In parental GEO and PC3 cells, enzastaurin in combination with
gefitinib had a synergistic effect on growth inhibition, particularly
with lower doses (data not shown). Interestingly, we observed that
in gefitinib-resistant cancer cell lines, GEO-GR and PC3-GR,
enzastaurin reverted the resistance to gefitinib. In fact, Figure 3C
and D demonstrates that the combination treatment caused a
synergistic inhibition of colony formation also in these resistant
cancer cells.
Enzastaurin combined with gefitinib causes potent
antitumour activity in xenografted nude mice
BALB/c nude mice xenografted with GEO tumours were treated
with enzastaurin and gefitinib, alone and in combination
(Figure 4). On day 63, 9 weeks after tumour injection, all untreated
mice reached the maximum allowed tumour size of 2cm
3.
Enzastaurin or gefitinib caused inhibition of tumour growth in
mice bearing GEO xenografts. When enzastaurin and gefitinib
were used in combination, a potent cooperative antitumour
activity was observed. Comparison of tumour sizes among
different treatment groups evaluated by the Student’s t-test was
statistically significant (Figure 4A). As compared to 5 weeks
median survival in control mice, the survival of mice treated with
enzastaurin or gefitinib was 9 and 10 weeks, respectively
(Figure 4B). Enzastaurin plus gefitinib did not reach a median
survival, because at the end of the experiments, 80% of mice were
still alive.
We treated with enzastaurin and gefitinib, alone and in
combination, also BALB/c nude mice xenografted with
GEO-GR tumours. This tumours grew more aggressively than
GEO wild-type, achieving the maximum allowed tumour size
of 2cm
3 in 6 weeks compared to the 9 weeks of GEO control
group. Mice bearing GEO-GR tumours treated with enzastaurin
alone reached this size 14 weeks after tumour injection, showing
B50% growth inhibition, as compared with control after 7 weeks.
As expected, treatment with gefitinib did not inhibit the growth
of these gefitinib-resistant tumours. Enzastaurin plus gefitinib
in combination caused a remarkable cooperative antitumour
activity, resulting in a tumour size of only 1cm
3 13 weeks
after treatment start. No relevant treatment-related side effects
were observed. Comparison of tumour sizes among different
treatment groups evaluated by the Student’s t-test was statis-











































































1       2       3      4     5      6      7      8
Figure 2 (A) Lane 1, GEO cells untreated; lane 2, GEO cells treated
with enzastaurin; lane 3, GEO-GR cells untreated; lane 4, GEO-GR cells
treated with enzastaurin; lane 5, PC3 cells untreated; lane 6, PC3 cells
treated with enzastaurin; lane 7, PC3-GR cells untreated; lane 8, PC3-GR
cells treated with enzastaurin. Cell lysates treated in vitro on days 0 and 2
were collected on day 5. Bars, s.d. (B) ELISA assay for VEGF was done on
total lysates from human cancer cell lines treated with 1mM enzastaurin for
2 days. Lane 1, GEO; lane 2, GEO-CR; lane 3, GEO-GR; lane 4, PC3; lane 5,
PC3-GR; lane 6, MDA-468. (C) ELISA assay for VEGF was done on
conditioned medium collected from the same cell lines. Data are the
average of two different experiments, each performed in triplicate; bars, s.d.
Results were reported as pg per mg protein.
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sin enzastaurin-treated group and 5 weeks in control mice
(Figure 4D). Enzastaurin plus gefitinib did not reach a median
survival, because 80% of mice were still alive at the end of the
experiments.
Combination of enzastaurin and gefitinib inhibits the
expression of signalling proteins and VEGF in GEO-GR
xenografts
We analysed the effect of treatment on the expression of a
variety of proteins playing a critical role in cancer cell proli-
feration and angiogenesis in GEO-GR tumours. Western blotting
analysis was performed on cell lysates from tumours removed at
the end of the third week of treatment, on day 25. As shown in
Figure 5A, enzastaurin did not affect the total amount of Akt,
p70S6K and GSK3b, but inhibited their activated forms pAkt,
pp70S6K and pGSK3b, and inhibited VEGF expression. Gefitinib
did not affect the expression of all signalling proteins observed.
When the two agents were used in combination, a more potent
inhibition on protein expression was observed.
Combination of enzastaurin and gefitinib reduces the
levels of human VEGF in GEO-GR tumour specimens and
mice serum
To evaluate the effect of treatment on VEGF levels, we performed
ELISA assays on protein extracts from tumour specimens
(Figure 5B) and on serum of GEO-GR-bearing mice (Figure 5C).
Enzastaurin reduced the levels of VEGF both in the tumour
extracts and in the serum, whereas gefitinib alone had a modest
inhibitory activity. The combination of the two drugs markedly
inhibited the VEGF production. On the contrary, neither single
agent nor their combination affected mVEGF as compared with
untreated mice (data not shown).
DISCUSSION
The EGFR pathway is also implicated in several intracellular
processes that control growth and angiogenesis. Monoclonal
antibodies or TKIs targeting EGFR are today used in clinical
practice (Mendelsohn and Baselga, 2006; Ciardiello and Tortora,
2008). However, molecular changes in EGFR-dependent or
EGFR-independent signalling pathways can lead to resistance to
EGFR inhibitors (Morgillo and Lee, 2005; Ono and Kuwano,
2006). In fact, cancer cells may acquire resistance to EGFR
inhibitors by increasing the expression and/or the activity of
several signalling proteins downstream to EGFR, including
pMAPK, pAkt and VEGF, which represent the major escape
pathways for EGFR inhibition (Ciardiello et al, 2004; Zhang et al,
2004; Morgillo and Lee, 2005). These same resistance mechanisms
occur in GEO-GR and PC3-GR cells as compared to their parental
counterparts (Ciardiello et al, 2004; present work and unpublished
observations). We and others have shown on these bases the
therapeutic advantage of a simultaneous blockade of EGFR and
VEGF/VEGFRs (Ciardiello et al, 2000, 2004; Kerbel and Folkman,
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Figure 3 (A and B) Effect of enzastaurin and gefitinib, alone and in combination, on the soft agar growth of GEO-GR and PC3-GR cells. Growth inhibition
results are expressed as the percentage of the number of colonies developed in each of the different treatment wells compared with the absolute number of
colonies developed in the untreated control group. Data represent the average of at least two different experiments run in triplicate. (C and D) Synergistic
effect of enzastaurin and gefitinib in combination on GEO-GR and PC3-GR cell growth inhibition. The data represent the plot of CIs, a quantitative measure
of the degree of combination treatment for a given end point of the inhibition effect. The CI values of o1, 1 and 41 indicate synergy, additivity and
antagonism, respectively. Each point is the mean of at least three different replicate experiments.
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s2002; Tortora et al, 2008). Therefore, novel agents able to inhibit
Akt and VEGF pathways may represent an important therapeutic
tool and they may also help in preventing the occurrence of
resistance to EGFR inhibitors.
In this context, PKCb, which activates the PI3K/Akt pathway
(Aeder et al, 2004; Kawakami et al, 2004) and transduces VEGFR
signalling, may be a valuable target. Enzastaurin is a novel
inhibitor of PKCb that interferes with angiogenesis and cell
proliferation and has shown good tolerability and activity in
clinical studies in glioblastoma and lymphoma (Fine et al, 2005;
Carducci et al, 2006).
In the present study, we have investigated the effect on growth
and protein expression of enzastaurin, used alone and in
combination with the EGFR TKI gefitinib, in human cancer cells
sensitive or resistant to gefitinib, in vitro and in nude mice.
We have shown that enzastaurin alone has an antiproliferative
effect on several human cancer cell lines EGFR inhibitor-sensitive
and EGFR inhibitor-resistant. Biochemical analysis demonstrated
that enzastaurin inhibits the expression of pAkt in all of the cancer
cell lines examined and suppresses the expression and secretion of
VEGF, especially in those cell lines resistant to EGFR inhibitors. In
addition, enzastaurin efficiently inhibits pGSK3b, a PKC and Akt
downstream target, and pp70S6K another Akt effector. Interest-
ingly, the degree of PKCb expression does not influence the
therapeutic efficacy of enzastaurin. We then investigated the effect
of enzastaurin in combination with gefitinib in cancer cell lines,
and we demonstrated a synergistic growth inhibitory effect in GEO
and PC3 cells, evident also with suboptimal doses of enzastaurin.
Interestingly, a synergism of action was observed also in the
gefitinib-resistant GEO-GR and PC3-GR cells, in which single-
agent gefitinib was totally ineffective. These results demonstrate
that enzastaurin, by targeting critical proteins such as pAkt and
VEGF pathways, is not only active when used alone, but also can
abrogate the resistance to EGFR inhibitors, strictly depending on
those proteins.
We translated this strategy in vivo, in nude mice bearing
sensitive and gefitinib-resistant GEO and GEO-GR colon tumours,
respectively. In GEO tumours, treatment with enzastaurin or
gefitinib caused an inhibition of tumour growth, and combination
of two drugs had a potent cooperative effect. In GEO-GR tumours,
gefitinib, as expected, was ineffective whereas enzastaurin alone
caused a significant inhibition of tumour growth. Enzastaurin in
combination with gefitinib revealed a marked antitumour effect,
resulting in 80% of mice still alive at the end of the experiments.
Moreover, a western blot analysis performed on tumour specimens
to evaluate the effect of treatment on protein expression revealed
that, whereas gefitinib alone was ineffective, enzastaurin was able
to inhibit pAkt, pp70S6K, pGSK3b and VEGF, and the combination
of the two agents caused a more efficient inhibition of the above
proteins. ELISA assay of tumour and blood samples confirmed that
the combination treatment inhibited the expression and the
secretion of VEGF.
Taken together, all the above data demonstrate that enzastaurin
is active on tumour proliferation and angiogenesis of cancer cells
sensitive and resistant to EGFR inhibitors. Importantly, enzastaurin
has a cooperative effect with gefitinib and is able to overcome and
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Figure 4 Cooperative effect of enzastaurin and gefitinib on tumour growth and survival of mice bearing human colon cancer xenografts GEO (A and B)
and GEO-GR (C and D). (A–C) After 7 days following tumour injection, 10 mice were randomised to receive the treatment. The Student’s t-test was used
to compare tumour sizes among different treatment groups at day 56 following cell injection. Statistically significant differences were observed for enzastaurin
vs control (two-sided Po0.0001), enzastaurinþgefitinib vs control (two-sided Po0.0001) and vs enzastaurin (two-sided Po0.0001). Bars, s.d. (B–D)
Median survival in GEO (B) and GEO-GR (D) xenografts.
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srevert the resistance to gefitinib in cancer cells resistant to this
anti-EGFR drug, likely due to the ability of enzastaurin to inhibit
the Akt and VEGF pathways, directly responsible for the escape
mechanisms activated in tumours resistant to EGFR inhibitors.
Therefore, enzastaurin in combination with anti-EGFR drugs may
be proposed as a novel therapeutic strategy worth further
investigation in a clinical setting.
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Figure 5 (A) Western blotting was performed on total lysates from tumour specimens of two mice of GEO-GR killed on day 25 and treated as in (C).
Lane 1, untreated control; lane 2, gefitinib; lane 3, enzastaurin; lane 4, gefitinib plus enzastaurin. (B and C) ELISA assays for hVEGF were performed on total
lysates from tumour specimens (B) and on serum (C) of two mice of GEO-GR killed on day 25.
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